Exclusion criteria 1. Patients cannot be simultaneously enrolled on other treatment studies. 2. Any contraindication to receiving GMCSF based vaccine products. 3. Patients with any of the following cardiac conditions: a. Symptomatic restrictive cardiomyopathy b. Unstable angina within 4 months prior to enrollment c. New York Heart Association functional class III -IV heart failure on active treatment d. Symptomatic pericardial effusion 4. Patients wi th any clinically significant autoimmune disease uncontrolled with treatment. 6304p Protocol 118 04/06/2016 12 5.